Walleye Capital’s KALA BIO KALA Stock Holding History

Walleye Capital’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-15	Closed	-$96	–	2207
2021 Q3	$96	Buy	+15	New	+$129K	﹤0.01%	1341

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VAFP

Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's KALA Position: Q4 2021 in Review

Walleye Capital sold out of KALA BIO (KALA) in Q4 2021, closing a stake of 15 shares — an estimated $96 sold.

Walleye Capital first reported a position in KALA in Q3 2021 and held it in 1 quarter. The position peaked at $96 in Q3 2021. 79 funds tracked by Wall St. Rank hold KALA as of Q4 2021.

Walleye Capital reported no remaining KALA BIO position as of Q4 2021 after selling out during the quarter.
Walleye Capital sold 15 KALA BIO shares in Q4 2021, an estimated $96.
Walleye Capital first reported a position in KALA BIO in Q3 2021 and held it in 1 quarter.
Walleye Capital's KALA BIO position peaked at $96 in Q3 2021.
79 funds tracked by Wall St. Rank held KALA BIO as of Q4 2021.

Based on Walleye Capital's 13F filing for Q4 2021, filed 3 Mar 2022.